MX2024003537A - Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. - Google Patents

Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Info

Publication number
MX2024003537A
MX2024003537A MX2024003537A MX2024003537A MX2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A
Authority
MX
Mexico
Prior art keywords
methods
subject
treating
cedazuridine
decitabine
Prior art date
Application number
MX2024003537A
Other languages
English (en)
Spanish (es)
Inventor
Harold Keer
Mohammad Azab
Yong Hao
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2024003537A publication Critical patent/MX2024003537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024003537A 2021-09-21 2022-09-21 Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. MX2024003537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
PCT/US2022/076757 WO2023049731A2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Publications (1)

Publication Number Publication Date
MX2024003537A true MX2024003537A (es) 2024-05-03

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003537A MX2024003537A (es) 2021-09-21 2022-09-21 Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Country Status (10)

Country Link
US (1) US20250000888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4404940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531799A (cg-RX-API-DMAC7.html)
KR (1) KR20240064656A (cg-RX-API-DMAC7.html)
CN (1) CN118201622A (cg-RX-API-DMAC7.html)
AU (1) AU2022348907B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003537A (cg-RX-API-DMAC7.html)
TW (1) TW202327625A (cg-RX-API-DMAC7.html)
WO (1) WO2023049731A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US10683552B2 (en) * 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Also Published As

Publication number Publication date
JP2024531799A (ja) 2024-08-29
US20250000888A1 (en) 2025-01-02
AU2022348907B2 (en) 2026-07-16
WO2023049731A2 (en) 2023-03-30
AU2022348907A1 (en) 2024-04-11
WO2023049731A3 (en) 2023-05-04
TW202327625A (zh) 2023-07-16
CN118201622A (zh) 2024-06-14
EP4404940A4 (en) 2025-07-30
EP4404940A2 (en) 2024-07-31
CA3232623A1 (en) 2023-03-30
KR20240064656A (ko) 2024-05-13

Similar Documents

Publication Publication Date Title
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
MX2021015993A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
MX2021004231A (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos.
MX2020004005A (es) Terapias genicas para los trastornos lisosomales.
CR20170406A (es) Arni variante
MX2017000578A (es) Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.
CR11687A (es) Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
MX2015012739A (es) Composiciones y metodos para tratar la mucopolisacaridosis tipo 1.
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2017009913A (es) Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes.
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
AR112103A1 (es) Compuestos para el tratamiento de tnbc
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
MX2019014330A (es) Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax.
MX2021004329A (es) 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos.
CL2019003743A1 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes.
CO2022007910A2 (es) Tratamientos contra el cáncer dirigidos a las células madre cancerosas
MX2017005419A (es) Tratamiento o prevencion de anemia en mamiferos no humanos preñados.
WO2023049731A3 (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
MX2023006937A (es) Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos.
CL2024000114A1 (es) Compuestos terapéuticos y procedimientos.